Document:

Exhibit 10.11

 

FIRST AMENDMENT TO MARKETING AGREEMENT

 

This FIRST AMENDMENT TO MARKETING
AGREEMENT (the “Amendment”) is dated and effective as of July 27, 2017 (the “Amendment Date”),
by and between NOCIMED, INC. a Delaware corporation with its principal place of business at 370 Convention Way, Redwood City, CA
94063 (“Nocimed”), and NUVASIVE, INC., a Delaware corporation with its principal place of business at
7475 Lusk Boulevard, San Diego, CA 92121 (“NuVasive”). Capitalized terms used but not defined herein shall have
the meanings assigned to them in the Marketing Agreement (as defined below).

 

WHEREAS, the parties
previously entered into that certain Marketing Agreement, dated February 18, 2015 (the “Marketing Agreement”);
and

 

WHEREAS, the parties
now desire to amend the Marketing Agreement in certain respects on the terms and conditions set forth herein.

 

NOW, THEREFORE, the parties hereby agree as follows:

 

1.       AMENDMENT.

 

(a)         Section 2.1(a) of the Marketing Agreement is hereby amended and restated in its entirety as follows:

 

“Activities: NuVasive shall use
its commercially reasonable efforts to promote and market the Technology worldwide during the Term. The parties shall mutually share with
one another data from their respective activities regarding clinical, regulatory, promotion and marketing efforts related to the Technology
with the intention of informing and optimizing the clinical and commercial partnership strategy regarding the Technology.”

 

(b)         Section 3.1 of the Marketing Agreement is hereby amended and restated in its entirety as follows:

 

“Compensation to NuVasive. As
compensation for NuVasive’s promotional and marketing activities with respect to the Technology under this Agreement, Nocimed
shall pay to NuVasive a commission (the “Commission”) equal to (a) twenty percent (20%) of aggregate
Technology Sales which occur during the period commencing on the Effective Date and continuing until the expiration of the
“Restrictive Period” (as defined in that certain Right of First Offer Agreement, dated February 18, 2015, by and between
Nocimed and NuVasive (the “ROFO Agreement”)), subject to extension concurrent with any renewal of this
Agreement as provided in Section 6.1 and to earlier termination upon any termination of this Agreement in accordance with Section
6.2 (the “Commission Term”); and (b) in addition to the Commission paid during the Commission Term under
sub-section (a), twenty percent (20%) of aggregate Technology Sales which occur during the eighteen (18) month period immediately
following the termination of this Agreement (the “Tail Period”), and are received from customer,
distributor or other arrangements established prior to the termination of this Agreement; provided, however, that in the case
that this Agreement terminates before the expiration of the Restrictive Period, then only such portion of the Tail Period that
extends beyond and does not overlap concurrently with the Restrictive Period shall apply with respect to payments under this
sub-section (b). For clarity, NuVasive shall receive the Commission on all such Technology Sales, regardless of whether such
installation or sales result (directly or indirectly) from any promotional or marketing activities of NuVasive.”

 

 

 

 

    	 	1	 

     

    

 

(c)         Section
6.1 of the Marketing Agreement is hereby amended and restated in its entirety as follows:

 

“Term. The term of this Agreement
will commence on the Effective Date and continue until the earlier occurrence of the expiration of the “Restrictive Period”
or the consummation of a “Sale Event” (as those terms are defined in that certain ROFO Agreement) (the “Initial
Term”), subject to extension as provided in this Section 6.1 and to earlier termination in accordance with Section 6.2 (the
“Term”). This Agreement shall automatically renew for successive three year periods (each, a “Renewal
Term”) at the end of the Initial Term and each Renewal Term thereafter, unless at least 90 days before the date this Agreement
would otherwise expire, either party notifies the other of its intention not to renew this Agreement; provided, however, any such
Renewal Term shall terminate upon the consummation of a Sale Event.”

 

2.       GENERAL.

 

(a)         This
Amendment shall be effective for all purposes as of the Amendment Date. Except as expressly modified herein, the Marketing Agreement
shall continue in full force and effect in accordance with its original terms.

 

(b)         The
Marketing Agreement, including as herein amended by and integrated with this Amendment, comprises the sole and exclusive agreement and
consent of the parties, and the terms of which shall prevail over and amend or modify any otherwise conflicting term of any other prior
or contemporaneous agreement or rights of the parties, regarding the subject matter hereof.

 

(c)         This
Amendment may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and
the same document. Electronic signatures shall be effective as original signatures.

 

 

 

[Signature Page Follows]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	2	 

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Amendment as of the Amendment Date.

 

	NOCIMED, INC.	 	NUVASIVE, INC.
	 	 	 	 	 
	By:	/s/ James C. Peacock III	 	By:	/s/ Greg Lucier
	 	Name: James C. Peacock III	 	 	Name: Greg Lucier
	 	Title: Chief Executive Officer	 	 	Title: Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	3Exhibit 10.13

 

NOCIMED, INC.

 

AMENDMENT NO. 1 TO

 

SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENT

 

This Amendment No. 1 to Series
B-1 Preferred Stock Purchase Agreement (the “Amendment”) is made as of February 1, 2018 (the “Amendment
Effective Date”) by and between Nocimed, Inc., a Delaware corporation (the “Company”), and the
purchaser set forth on the signature page hereto (the “Purchaser”).

 

WHEREAS, the Company and the
Purchaser entered into that certain Series B-1 Preferred Stock Purchase Agreement, dated as of July 27, 2017, by and among the Company
and the purchasers listed on Exhibit A thereto (the “Purchase Agreement”), pursuant to which the Company sold
and issued shares of the Company’s Series B-1 Preferred Stock to the purchasers listed on Exhibit A thereto;

 

WHEREAS, the Company and the
Purchaser wish to amend the Purchase Agreement as set forth herein; and

 

WHEREAS, pursuant to Section
6.6 of the Purchase Agreement, the Purchase Agreement may be amended only with the written consent of the Company and the holders of a
majority of the Shares (as defined in the Purchase Agreement) purchased or agreed to be purchased pursuant to the Purchase Agreement;

 

WHEREAS, the undersigned together
represent the Company and the holders of a majority of the Shares purchased or agreed to be purchased pursuant to the Purchase Agreement.

 

NOW, THEREFORE, BE IT RESOLVED,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.              
Amendment of Purchase Agreement. The first sentence of Section 2.2 of the Purchase Agreement is hereby amended and restated
to read in its entirety as follows:

 

“At any time prior to March 31, 2018,
subject to the approval of the Company’s Board of Directors (the “Board”), the Company may sell in one
or more additional closings (each, an “Additional Closing”, and, together with the Initial Closing, each a “Closing”)
up to the balance of the Shares not sold at the Initial Closing (the “Additional Shares”) to one or more existing
or new investors approved in writing by NuVasive, Inc. (“NuVasive”), which approval shall not be unreasonably
withheld (the “Additional Purchasers”).”

 

2.              
Miscellaneous.

 

(a)       Governing
Law. This Amendment shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws
that might otherwise govern under applicable principles of conflicts of law.

 

(b)       Entire Agreement;
Amendment.

 

(i)             
This Amendment, the Purchase Agreement and any documents referenced herein and therein, sets forth the entire agreement and understanding
of the parties hereto relating to the subject matter herein and supersede all prior agreements and understandings relating to such subject
matter.

 

(ii)           
No modification of or amendment to this Amendment, nor any waiver of any rights under this Amendment, shall be effective unless
in writing signed by the parties to this Amendment.

 

(iii)         
Except as expressly modified by this Amendment, the terms of the Purchase Agreement remain unchanged, and the Purchase Agreement
shall remain in full force and effect as so modified.

 

(c)       Counterparts.
This Amendment may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall
constitute one instrument.

 

[Signature Pages Follow]

 

 

    	 	1	 

     

    

 

The parties have executed
this Amendment No. 3 to Series B-1 Preferred Stock Purchase Agreement as of the Amendment Effective Date.

 

	COMPANY:	PURCHASER:
	 	 
	Nocimed, Inc.	NuVasive, Inc.
	 	 
	By: /s/ Brett Lanuti	By: /s/ Greg Lucier
	 	 
	Name:   Brett Lanuti	Name:  Greg Lucier
	 	 
	Title:Chief Executive Officer	Title Chief Executive Officer
	 	 
	 	 
	Address:	Address:
	370 Convention Way	7475 Lusk Boulevard
	Redwood City, CA 94063	San Diego, CA 92121
	ATTN: Brett Lanuti	ATTN:
	E-mail: blanuti@nocimed.com	E-mail:

 

 

SIGNATURE PAGE TO THE AMENDMENT NO. 1 TO

SERIES B-I PREFERRED STOCK PURCHASE AGREEMENT
OF NOCIMED, INC.

 

 

 

    	 	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]